Neuropeptide Signaling Pathway represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Neuropeptides are small protein-like molecules (typically 3-40 amino acids) used by neurons to communicate with each other. They represent one of the oldest and most evolutionarily conserved signaling systems in the nervous system, with roles spanning modulation of synaptic transmission, regulation of behavior, coordination of neuroendocrine responses, and control of fundamental physiological processes. Unlike classical neurotransmitters that are packaged in small synaptic vesicles, neuropeptides are stored in large dense-core vesicles and released from varicosities and somata, enabling volume transmission over longer distances[1]. [2]
Neuropeptides are derived from larger precursor proteins (prepropeptides) that undergo proteolytic processing in the secretory pathway. They can be classified by their anatomical distribution, receptor usage, or functional role: [3]
| Neuropeptide | Primary Function | Disease Relevance | [4]
|--------------|------------------|-------------------| [5]
| Vasoactive Intestinal Peptide (VIP) | Circadian rhythms, learning, memory, immunomodulation | AD, circadian disorders | [6]
| Substance P | Pain transmission, nausea, neuroinflammation | PD, depression, pain disorders |
| Somatostatin | Inhibition of hormone release, memory modulation | AD, epilepsy |
| Neuropeptide Y (NPY) | Appetite regulation, stress response, anxiety | Depression, obesity, epilepsy |
| Oxytocin | Social bonding, trust, uterine contraction | Social cognition, autism |
| Vasopressin | Water retention, blood pressure, social behavior | Social memory, stress |
| Corticotropin-releasing hormone (CRH) | Stress response, HPA axis activation | Depression, anxiety, AD |
| Hypocretins/Orexins | Wakefulness, appetite, reward | Narcolepsy, PD |
| Calcitonin Gene-Related Peptide (CGRP) | Vasodilation, migraine | Migraine, PD |
Neuropeptides signal through distinct mechanisms that differ from classical neurotransmitter transmission:
Neuropeptides modulate both long-term potentiation (LTP) and long-term depression (LTD), the cellular correlates of learning and memory. VIP, somatostatin, and NPY are particularly important in regulating hippocampal plasticity[2:1].
The CRH and urocortin family of peptides orchestrate the hypothalamic-pituitary-adrenal (HPA) axis response to stress. Dysregulation of this system is implicated in major depression, anxiety disorders, and AD[3:1].
NPY/AgRP neurons in the arcuate nucleus are the primary orexigenic (appetite-stimulating) population, while POMC/CART neurons produce anorexigenic (appetite-suppressing) signals. This system is affected in AD and PD[4:1].
Hypocretins/orexins stabilize wakefulness and regulate the sleep-wake cycle. Loss of hypocretin neurons causes narcolepsy, and dysfunction is implicated in PD sleep disorders[5:1].
Substance P and CGRP transmit pain signals from peripheral nociceptors to central nervous system pain centers. These peptides are therapeutic targets for migraine and chronic pain[6:1].
Neuropeptide alterations are prominent in AD:
The study of Neuropeptide Signaling Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 6 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 26%
van den Pol AN. Neuropeptide transmission in brain circuits. Neuron. 2012. ↩︎
Barker DJ, et al. Neuropeptide systems as therapeutic targets for psychiatric disorders. Pharmacol Rev. 2023. ↩︎ ↩︎
Holsboer F. The role of peptides in anxiety disorders. CNS Spectr. 2000. ↩︎ ↩︎
Zhong Y, et al. Neuropeptide Y and its receptors in neurodegenerative diseases. J Mol Neurosci. 2021. ↩︎ ↩︎
Baumann CR, et al. Hypocretin/orexin deficiency in human narcolepsy. Lancet. 2019. ↩︎ ↩︎
Mantyh PW. Neuropeptide function in pain and migraine. Headache. 2022. ↩︎ ↩︎